ping an-杏耀平台代理注册

c&o completed the clinical trial of rabeprazole sodium for injection in 2011 and will be the first to be approved for production and marketing this year. after that, the product will be available for investment on a provincial basis nationwide. as a new generation of proton pump inhibitor (anti-ulcer drug), rabeprazole sodium for injection has great market potential with outstanding product advantages and high safety, and it will become the leading product of proton pump inhibitor.

advantages of rabeprazole sodium for injection:

1.multi-targeted inhibition of four channels of proton pump for faster and stronger acid inhibition

2.highest pka value, ensuring strong and long-lasting acid inhibition

3.the only ppi that is metabolized by a “non-enzymatic pathway”, with little individual variation in clinical use and less drug interactions

c&o will attend the 71st suzhou drug trade fair on april 26-28, 2014, at booth no. 3a808, and will hold the “launch conference of rabeprazole sodium for injection of c&o” on april 27, 9:00 am-12:00 pm in conference room 6209. you are cordially invited to attend!

if you are interested in cooperation, please fill out the attached appointment registration form and send it to huanglijun@changao.com. we will send you an invitation letter by mail and look forward to your visit!

for more information, please call 0755-25527386 (ms. huang) or 0755-25413959 (ms. guo).

appendix: registration form for agents of rabeprazole sodium for injection 20140401.doc

contacts for rabeprazole sodium for injection (aobo ping) in provinces.xls

first draft of rabe color page 014-1.rar